Skip to search formSkip to main contentSkip to account menu

ABR-217620

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Antineoplastic Agentsnaptumomab estafenatox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The Tumor Targeted Superantigen ABR-217620 Selectively Engages TRBV7-9 and Exploits TCR-pMHC Affinity Mimicry in Mediating T Cell Cytotoxicity
The T lymphocytes are the most important effector cells in immunotherapy of cancer. The conceptual objective for developing the… 
2010
2010
Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has… 
2007
2007
An open label phase I study of ABR-217620 in combination with docetaxel in patients with NSCLC.
A163 Background ABR-217620 (naptumomab estafenatox) is a recombinant fusion protein consisting of the 5T4Fab moiety genetically… 
2006
2006
An open label phase I study of ABR-217620, a fusion protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer.
3083 Background: ABR-217620 (naptumomab estafenatox) is a recombinant fusion protein that consists of the 5T4Fab moiety… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)